Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 11, 2007, Pages 1138-1145

  Evgenov, Oleg V ^a   Kohane, Daniel S ^b,c   Bloch, Kenneth D ^a   Stasch, Johannes Peter ^d   Volpato, Gian P ^a   Bellas, Evangelia ^c   Evgenov, Natalia V ^a   Buys, Emmanuel S ^a   Gnoth, Mark J ^d   Graveline, Amanda R ^a   Liu, Rong ^a   Hess, Dean R ^a,e   Langer, Robert ^c   Zapol, Warren M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d PharmaResearch Center   (Germany)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BAY 41 2272; BAY 41 8543; BAY 58 2667; Pulmonary hypertension; Soluble guanylate cyclase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALBUMIN; CYCLIC GMP; DIPALMITOYLPHOSPHATIDYLCHOLINE; EXCIPIENT; GUANYLATE CYCLASE ACTIVATOR; HEME; LACTOSE; NITRIC OXIDE; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL OXYGEN SATURATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRY POWDER; ENDOTRACHEAL TUBE; INTRAVASCULAR CATHETER; LAMB; LUNG ARTERY PRESSURE; LUNG VASODILATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASODILATATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BENZOIC ACIDS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GUANYLATE CYCLASE; INJECTIONS, INTRAVENOUS; LUNG; MORPHOLINES; NITRIC OXIDE; OXADIAZOLES; PARTICLE SIZE; PHOSPHODIESTERASE INHIBITORS; POWDERS; PULMONARY CIRCULATION; PURINONES; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINOXALINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SHEEP; VASODILATION;

EID: 36849026670     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200707-1121OC     Document Type: Article

References (29)

1. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-1431.
2. Hoeper MM, Rubin LJ. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med 2006;173:499-505.
3. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000;80:1337-1372.
4. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-768.
5. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004;110:2253-2259.
6. Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005;289:L798-L806.
7. Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006;90:135-144.
8. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-295.
9. Lowson SM. Inhaled alternatives to nitric oxide. Crit Care Med 2005;33:S188-S195.
10. Paton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007;6:67-74.
11. Evgenov OV, Petersen B, Bellas E, Evgenov NV, Stasch JP, Hess DR, Ichinose F, Bloch KD, Langer R, Kohane DS, et al. Inhalation of microparticles containing stimulators of soluble guanylate cyclase produces potent pulmonary vasodilation [abstract]. Proc Am Thorac Soc 2006;3:A686.
12. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R, Edwards DA. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999;16:1735-1742.
13. Evgenov OV, Busch CJ, Evgenov NV, Liu R, Petersen B, Falkowski GE, Petho B, Vas A, Bloch KD, Zapol WM, et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;290:L723-L729.
14. Schuhmacher J, Zimmer D, Tesche F, Pickard V. Matrix effects during analysis of plasma samples by electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their elimination. Rapid Commun Mass Spectrom 2003;17:1950-1957.
15. Gessler T, Schmehl T, Olschewski H, Grimminger F, Seeger W. Aerosolized vasodilators in pulmonary hypertension. J Aerosol Med 2002;15:117-122.
16. Choi WS, Murthy GG, Edwards DA, Langer R, Klibanov AM. Inhalation delivery of proteins from ethanol suspensions. Proc Natl Acad Sci USA 2001;98:11103-11107.
17. Ben-Jebria A, Chen D, Eskew ML, Vanbever R, Langer R, Edwards DA. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999;16:555-561.
18. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998;85:379-385.
19. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-215.
20. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002;135:333-343.
21. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002;136:773-783.
22. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.
23. Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, Rodman DM. Inhibition of cyclic 3′,5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996;97:172-179.
24. Priviero FB, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, Antunes E. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol 2005;32:728-734.
25. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-113.
26. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004;109:3106-3111.
27. Chockalingam A, Gnanavelu G, Venkatesan S, Elangovan S, Jagannathan V, Subramaniam T, Alagesan R, Dorairajan S. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005;99:91-95.
28. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996;50:1-5.
29. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arun Kumar HS, Meurer S, Deile M, Taye A, Knorr A, Lapp H, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561.